世界の関節リウマチ治療薬市場2024-2028

◆英語タイトル:Global Rheumatoid Arthritis Drugs Market 2024-2028

Technavioが発行した調査報告書(IRTNTR73313-23)◆商品コード:IRTNTR73313-23
◆発行会社(リサーチ会社):Technavio
◆発行日:2023年10月30日
◆ページ数:約120
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後24時間以内)
◆調査対象地域:北米、ヨーロッパ、アジア、その他地域
◆産業分野:医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,500 ⇒換算¥380,000見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD4,000 ⇒換算¥608,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行・送付致します。(請求書発行日より2ヶ月以内の銀行振込条件、カード払いに変更可)
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。

❖ レポートの概要 ❖

関節リウマチ治療薬の世界市場 2024-2028関節リウマチ治療薬市場は、2023年から2028年にかけて1億6,045万2,000万米ドルの成長が予測され、予測期間中のCAGRは7.5%で加速すると予測されています。当レポートでは、関節リウマチ治療薬市場の全体的な分析、市場規模と予測、動向、成長促進要因、課題に加え、約25のベンダーを網羅したベンダー分析も提供しています。
当レポートでは、現在の市場シナリオ、最新動向と促進要因、市場環境全体に関する最新分析を提供しています。RA症例の増加、リウマチ専門医の増加、診断方法の改善、RAに対する手頃な価格の生物学的製剤の必要性などが市場を牽引しています。

Technavioの関節リウマチ治療薬市場は以下のようにセグメント化されています。
薬剤クラス別
- 疾患修飾性抗リウマチ薬
- 非ステロイド性抗炎症薬
- コルチコステロイド

タイプ別
- 生物製剤
- 低分子

地域別
- 北米
- 欧州
- アジア
- その他の地域(ROW)

本調査では、今後数年間における関節リウマチ治療薬市場の成長を促進する主な要因の1つとして、RAに対する医療保険制度の提供を挙げています。また、RA治療のための生物学的製剤/バイオシミラーの使用やRA治療のための遺伝子治療の使用は、市場の大きな需要につながるでしょう。

本レポートでは、関節リウマチ治療薬市場について以下の分野をカバーしています。
- 関節リウマチ治療薬市場規模
- 関節リウマチ治療薬市場予測
- 関節リウマチ治療薬市場産業分析

堅牢なベンダー分析は、クライアントが市場での地位を向上させるために設計されており、これに伴い、本レポートでは、AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bristol Myers Squibb Co., Eli Lilly and Co., F. Hoffmann La Roche Ltd., Galmed Pharmaceuticals Ltd., Genor Biopharma Holdings Ltd., Gilde Healthcare, Gilead Sciences Inc., GlaxoSmithKline Plc, Johnson and Johnson, Kangstem Biotech Co. Ltd., Novartis AG, Oryn Therapeutics, Pfizer Inc., Sanofi, Sorrento Therapeutics Inc., Taisho Pharmaceutical Holdings Co. Ltd., and UCB SA.などを分析しています。また、関節リウマチ治療薬市場の分析レポートには、市場成長に影響を与える今後の動向や課題に関する情報も含まれています。これは、企業が戦略を立て、来るべき成長機会をすべて活用するのに役立つものです。

本調査は、業界の主要参加者からのインプットを含め、一次情報と二次情報を客観的に組み合わせて実施しました。当レポートでは、主要ベンダーの分析に加え、包括的な市場とベンダーの状況を掲載しています。
当調査会社は、利益、価格、競争、プロモーションなどの主要パラメータの分析により、複数の情報源からのデータを調査、統合、総括する方法で、市場の詳細な姿を提示しています。また、主要な業界インフルエンサーを特定することで、市場の様々な側面を提示しています。提示されるデータは包括的で信頼性が高く、一次および二次にわたる広範な調査の結果です。市場調査レポートは、正確な市場成長を予測するために、完全な競争環境と、質的・量的調査を用いた綿密なベンダー選定方法と分析を提供します。

1 エグゼクティブサマリー
2 市場状況
3 市場規模
4 過去の市場規模
5 ファイブフォース分析
6 関節リウマチ治療薬の世界市場:薬効別市場分析
7 関節リウマチ治療薬の世界市場:タイプ別市場分析
8 顧客状況
9 地域別状況
10 推進要因・課題・動向
11 企業状況
12 企業分析
13 付録

❖ レポートの目次 ❖

• 1 Executive Summary
o 1.1 Market overview
o Exhibit 01: Executive Summary – Chart on Market Overview
o Exhibit 02: Executive Summary – Data Table on Market Overview
o Exhibit 03: Executive Summary – Chart on Global Market Characteristics
o Exhibit 04: Executive Summary – Chart on Market By Geographical Landscape
o Exhibit 05: Executive Summary – Chart on Market Segmentation by Drug Class
o Exhibit 06: Executive Summary – Chart on Market Segmentation by Type
o Exhibit 07: Executive Summary – Chart on Incremental Growth
o Exhibit 08: Executive Summary – Data Table on Incremental Growth
o Exhibit 09: Executive Summary – Chart on Vendor Market Positioning
• 2 Market Landscape
o 2.1 Market ecosystem
o Exhibit 10: Parent market
o Exhibit 11: Market Characteristics
• 3 Market Sizing
o 3.1 Market definition
o Exhibit 12: Offerings of vendors included in the market definition
o 3.2 Market segment analysis
o Exhibit 13: Market segments
o 3.3 Market size 2023
o 3.4 Market outlook: Forecast for 2023-2028
o Exhibit 14: Chart on Global – Market size and forecast 2023-2028 ($ million)
o Exhibit 15: Data Table on Global – Market size and forecast 2023-2028 ($ million)
o Exhibit 16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
o Exhibit 17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
• 4 Historic Market Size
o 4.1 Global rheumatoid arthritis drugs market 2018 – 2022
o Exhibit 18: Historic Market Size – Data Table on global rheumatoid arthritis drugs market 2018 – 2022 ($ million)
o 4.2 Drug Class Segment Analysis 2018 – 2022
o Exhibit 19: Historic Market Size – Drug Class Segment 2018 – 2022 ($ million)
o 4.3 Type Segment Analysis 2018 – 2022
o Exhibit 20: Historic Market Size – Type Segment 2018 – 2022 ($ million)
o 4.4 Geography Segment Analysis 2018 – 2022
o Exhibit 21: Historic Market Size – Geography Segment 2018 – 2022 ($ million)
o 4.5 Country Segment Analysis 2018 – 2022
o Exhibit 22: Historic Market Size – Country Segment 2018 – 2022 ($ million)
• 5 Five Forces Analysis
o 5.1 Five forces summary
o Exhibit 23: Five forces analysis – Comparison between 2023 and 2028
o 5.2 Bargaining power of buyers
o Exhibit 24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
o 5.3 Bargaining power of suppliers
o Exhibit 25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
o 5.4 Threat of new entrants
o Exhibit 26: Threat of new entrants – Impact of key factors in 2023 and 2028
o 5.5 Threat of substitutes
o Exhibit 27: Threat of substitutes – Impact of key factors in 2023 and 2028
o 5.6 Threat of rivalry
o Exhibit 28: Threat of rivalry – Impact of key factors in 2023 and 2028
o 5.7 Market condition
o Exhibit 29: Chart on Market condition – Five forces 2023 and 2028
• 6 Market Segmentation by Drug Class
o 6.1 Market segments
o Exhibit 30: Chart on Drug Class – Market share 2023-2028 (%)
o Exhibit 31: Data Table on Drug Class – Market share 2023-2028 (%)
o 6.2 Comparison by Drug Class
o Exhibit 32: Chart on Comparison by Drug Class
o Exhibit 33: Data Table on Comparison by Drug Class
o 6.3 Disease-modifying anti-rheumatic drugs – Market size and forecast 2023-2028
o Exhibit 34: Chart on Disease-modifying anti-rheumatic drugs – Market size and forecast 2023-2028 ($ million)
o Exhibit 35: Data Table on Disease-modifying anti-rheumatic drugs – Market size and forecast 2023-2028 ($ million)
o Exhibit 36: Chart on Disease-modifying anti-rheumatic drugs – Year-over-year growth 2023-2028 (%)
o Exhibit 37: Data Table on Disease-modifying anti-rheumatic drugs – Year-over-year growth 2023-2028 (%)
o 6.4 Nonsteroidal anti-inflammatory drugs – Market size and forecast 2023-2028
o Exhibit 38: Chart on Nonsteroidal anti-inflammatory drugs – Market size and forecast 2023-2028 ($ million)
o Exhibit 39: Data Table on Nonsteroidal anti-inflammatory drugs – Market size and forecast 2023-2028 ($ million)
o Exhibit 40: Chart on Nonsteroidal anti-inflammatory drugs – Year-over-year growth 2023-2028 (%)
o Exhibit 41: Data Table on Nonsteroidal anti-inflammatory drugs – Year-over-year growth 2023-2028 (%)
o 6.5 Corticosteroids – Market size and forecast 2023-2028
o Exhibit 42: Chart on Corticosteroids – Market size and forecast 2023-2028 ($ million)
o Exhibit 43: Data Table on Corticosteroids – Market size and forecast 2023-2028 ($ million)
o Exhibit 44: Chart on Corticosteroids – Year-over-year growth 2023-2028 (%)
o Exhibit 45: Data Table on Corticosteroids – Year-over-year growth 2023-2028 (%)
o 6.6 Market opportunity by Drug Class
o Exhibit 46: Market opportunity by Drug Class ($ million)
o Exhibit 47: Data Table on Market opportunity by Drug Class ($ million)
• 7 Market Segmentation by Type
o 7.1 Market segments
o Exhibit 48: Chart on Type – Market share 2023-2028 (%)
o Exhibit 49: Data Table on Type – Market share 2023-2028 (%)
o 7.2 Comparison by Type
o Exhibit 50: Chart on Comparison by Type
o Exhibit 51: Data Table on Comparison by Type
o 7.3 Biologics – Market size and forecast 2023-2028
o Exhibit 52: Chart on Biologics – Market size and forecast 2023-2028 ($ million)
o Exhibit 53: Data Table on Biologics – Market size and forecast 2023-2028 ($ million)
o Exhibit 54: Chart on Biologics – Year-over-year growth 2023-2028 (%)
o Exhibit 55: Data Table on Biologics – Year-over-year growth 2023-2028 (%)
o 7.4 Small Molecules – Market size and forecast 2023-2028
o Exhibit 56: Chart on Small Molecules – Market size and forecast 2023-2028 ($ million)
o Exhibit 57: Data Table on Small Molecules – Market size and forecast 2023-2028 ($ million)
o Exhibit 58: Chart on Small Molecules – Year-over-year growth 2023-2028 (%)
o Exhibit 59: Data Table on Small Molecules – Year-over-year growth 2023-2028 (%)
o 7.5 Market opportunity by Type
o Exhibit 60: Market opportunity by Type ($ million)
o Exhibit 61: Data Table on Market opportunity by Type ($ million)
• 8 Customer Landscape
o 8.1 Customer landscape overview
o Exhibit 62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
• 9 Geographic Landscape
o 9.1 Geographic segmentation
o Exhibit 63: Chart on Market share By Geographical Landscape 2023-2028 (%)
o Exhibit 64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
o 9.2 Geographic comparison
o Exhibit 65: Chart on Geographic comparison
o Exhibit 66: Data Table on Geographic comparison
o 9.3 North America – Market size and forecast 2023-2028
o Exhibit 67: Chart on North America – Market size and forecast 2023-2028 ($ million)
o Exhibit 68: Data Table on North America – Market size and forecast 2023-2028 ($ million)
o Exhibit 69: Chart on North America – Year-over-year growth 2023-2028 (%)
o Exhibit 70: Data Table on North America – Year-over-year growth 2023-2028 (%)
o 9.4 Europe – Market size and forecast 2023-2028
o Exhibit 71: Chart on Europe – Market size and forecast 2023-2028 ($ million)
o Exhibit 72: Data Table on Europe – Market size and forecast 2023-2028 ($ million)
o Exhibit 73: Chart on Europe – Year-over-year growth 2023-2028 (%)
o Exhibit 74: Data Table on Europe – Year-over-year growth 2023-2028 (%)
o 9.5 Asia – Market size and forecast 2023-2028
o Exhibit 75: Chart on Asia – Market size and forecast 2023-2028 ($ million)
o Exhibit 76: Data Table on Asia – Market size and forecast 2023-2028 ($ million)
o Exhibit 77: Chart on Asia – Year-over-year growth 2023-2028 (%)
o Exhibit 78: Data Table on Asia – Year-over-year growth 2023-2028 (%)
o 9.6 Rest of World (ROW) – Market size and forecast 2023-2028
o Exhibit 79: Chart on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
o Exhibit 80: Data Table on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
o Exhibit 81: Chart on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
o Exhibit 82: Data Table on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
o 9.7 US – Market size and forecast 2023-2028
o Exhibit 83: Chart on US – Market size and forecast 2023-2028 ($ million)
o Exhibit 84: Data Table on US – Market size and forecast 2023-2028 ($ million)
o Exhibit 85: Chart on US – Year-over-year growth 2023-2028 (%)
o Exhibit 86: Data Table on US – Year-over-year growth 2023-2028 (%)
o 9.8 UK – Market size and forecast 2023-2028
o Exhibit 87: Chart on UK – Market size and forecast 2023-2028 ($ million)
o Exhibit 88: Data Table on UK – Market size and forecast 2023-2028 ($ million)
o Exhibit 89: Chart on UK – Year-over-year growth 2023-2028 (%)
o Exhibit 90: Data Table on UK – Year-over-year growth 2023-2028 (%)
o 9.9 China – Market size and forecast 2023-2028
o Exhibit 91: Chart on China – Market size and forecast 2023-2028 ($ million)
o Exhibit 92: Data Table on China – Market size and forecast 2023-2028 ($ million)
o Exhibit 93: Chart on China – Year-over-year growth 2023-2028 (%)
o Exhibit 94: Data Table on China – Year-over-year growth 2023-2028 (%)
o 9.10 Germany – Market size and forecast 2023-2028
o Exhibit 95: Chart on Germany – Market size and forecast 2023-2028 ($ million)
o Exhibit 96: Data Table on Germany – Market size and forecast 2023-2028 ($ million)
o Exhibit 97: Chart on Germany – Year-over-year growth 2023-2028 (%)
o Exhibit 98: Data Table on Germany – Year-over-year growth 2023-2028 (%)
o 9.11 France – Market size and forecast 2023-2028
o Exhibit 99: Chart on France – Market size and forecast 2023-2028 ($ million)
o Exhibit 100: Data Table on France – Market size and forecast 2023-2028 ($ million)
o Exhibit 101: Chart on France – Year-over-year growth 2023-2028 (%)
o Exhibit 102: Data Table on France – Year-over-year growth 2023-2028 (%)
o 9.12 Market opportunity By Geographical Landscape
o Exhibit 103: Market opportunity By Geographical Landscape ($ million)
o Exhibit 104: Data Tables on Market opportunity By Geographical Landscape ($ million)
• 10 Drivers, Challenges, and Trends
o 10.1 Market drivers
o 10.2 Market challenges
o 10.3 Impact of drivers and challenges
o Exhibit 105: Impact of drivers and challenges in 2023 and 2028
o 10.4 Market trends
• 11 Vendor Landscape
o 11.1 Overview
o 11.2 Vendor landscape
o Exhibit 106: Overview on Criticality of inputs and Factors of differentiation
o 11.3 Landscape disruption
o Exhibit 107: Overview on factors of disruption
o 11.4 Industry risks
o Exhibit 108: Impact of key risks on business
• 12 Vendor Analysis
o 12.1 Vendors covered
o Exhibit 109: Vendors covered
o 12.2 Market positioning of vendors
o Exhibit 110: Matrix on vendor position and classification
o 12.3 AbbVie Inc.
o Exhibit 111: AbbVie Inc. – Overview
o Exhibit 112: AbbVie Inc. – Product / Service
o Exhibit 113: AbbVie Inc. – Key news
o Exhibit 114: AbbVie Inc. – Key offerings
o 12.4 Amgen Inc.
o Exhibit 115: Amgen Inc. – Overview
o Exhibit 116: Amgen Inc. – Product / Service
o Exhibit 117: Amgen Inc. – Key offerings
o 12.5 Bristol Myers Squibb Co.
o Exhibit 118: Bristol Myers Squibb Co. – Overview
o Exhibit 119: Bristol Myers Squibb Co. – Product / Service
o Exhibit 120: Bristol Myers Squibb Co. – Key news
o Exhibit 121: Bristol Myers Squibb Co. – Key offerings
o 12.6 Eli Lilly and Co.
o Exhibit 122: Eli Lilly and Co. – Overview
o Exhibit 123: Eli Lilly and Co. – Product / Service
o Exhibit 124: Eli Lilly and Co. – Key news
o Exhibit 125: Eli Lilly and Co. – Key offerings
o 12.7 F. Hoffmann La Roche Ltd.
o Exhibit 126: F. Hoffmann La Roche Ltd. – Overview
o Exhibit 127: F. Hoffmann La Roche Ltd. – Business segments
o Exhibit 128: F. Hoffmann La Roche Ltd. – Key news
o Exhibit 129: F. Hoffmann La Roche Ltd. – Key offerings
o Exhibit 130: F. Hoffmann La Roche Ltd. – Segment focus
o 12.8 Genor Biopharma Holdings Ltd.
o Exhibit 131: Genor Biopharma Holdings Ltd. – Overview
o Exhibit 132: Genor Biopharma Holdings Ltd. – Product / Service
o Exhibit 133: Genor Biopharma Holdings Ltd. – Key offerings
o 12.9 Gilead Sciences Inc.
o Exhibit 134: Gilead Sciences Inc. – Overview
o Exhibit 135: Gilead Sciences Inc. – Product / Service
o Exhibit 136: Gilead Sciences Inc. – Key news
o Exhibit 137: Gilead Sciences Inc. – Key offerings
o 12.10 Johnson and Johnson
o Exhibit 138: Johnson and Johnson – Overview
o Exhibit 139: Johnson and Johnson – Business segments
o Exhibit 140: Johnson and Johnson – Key news
o Exhibit 141: Johnson and Johnson – Key offerings
o Exhibit 142: Johnson and Johnson – Segment focus
o 12.11 Kangstem Biotech Co. Ltd.
o Exhibit 143: Kangstem Biotech Co. Ltd. – Overview
o Exhibit 144: Kangstem Biotech Co. Ltd. – Product / Service
o Exhibit 145: Kangstem Biotech Co. Ltd. – Key offerings
o 12.12 Novartis AG
o Exhibit 146: Novartis AG – Overview
o Exhibit 147: Novartis AG – Business segments
o Exhibit 148: Novartis AG – Key offerings
o Exhibit 149: Novartis AG – Segment focus
o 12.13 Oryn Therapeutics
o Exhibit 150: Oryn Therapeutics – Overview
o Exhibit 151: Oryn Therapeutics – Product / Service
o Exhibit 152: Oryn Therapeutics – Key offerings
o 12.14 Pfizer Inc.
o Exhibit 153: Pfizer Inc. – Overview
o Exhibit 154: Pfizer Inc. – Product / Service
o Exhibit 155: Pfizer Inc. – Key news
o Exhibit 156: Pfizer Inc. – Key offerings
o 12.15 Sanofi
o Exhibit 157: Sanofi – Overview
o Exhibit 158: Sanofi – Business segments
o Exhibit 159: Sanofi – Key news
o Exhibit 160: Sanofi – Key offerings
o Exhibit 161: Sanofi – Segment focus
o 12.16 Sorrento Therapeutics Inc.
o Exhibit 162: Sorrento Therapeutics Inc. – Overview
o Exhibit 163: Sorrento Therapeutics Inc. – Business segments
o Exhibit 164: Sorrento Therapeutics Inc. – Key offerings
o Exhibit 165: Sorrento Therapeutics Inc. – Segment focus
o 12.17 UCB SA
o Exhibit 166: UCB SA – Overview
o Exhibit 167: UCB SA – Product / Service
o Exhibit 168: UCB SA – Key offerings
• 13 Appendix
o 13.1 Scope of the report
o 13.2 Inclusions and exclusions checklist
o Exhibit 169: Inclusions checklist
o Exhibit 170: Exclusions checklist
o 13.3 Currency conversion rates for US$
o Exhibit 171: Currency conversion rates for US$
o 13.4 Research methodology
o Exhibit 172: Research methodology
o Exhibit 173: Validation techniques employed for market sizing
o Exhibit 174: Information sources
o 13.5 List of abbreviations
o Exhibit 175: List of abbreviations

Exhibits:
Exhibits1: Executive Summary – Chart on Market Overview
Exhibits2: Executive Summary – Data Table on Market Overview
Exhibits3: Executive Summary – Chart on Global Market Characteristics
Exhibits4: Executive Summary – Chart on Market By Geographical Landscape
Exhibits5: Executive Summary – Chart on Market Segmentation by Drug Class
Exhibits6: Executive Summary – Chart on Market Segmentation by Type
Exhibits7: Executive Summary – Chart on Incremental Growth
Exhibits8: Executive Summary – Data Table on Incremental Growth
Exhibits9: Executive Summary – Chart on Vendor Market Positioning
Exhibits10: Parent market
Exhibits11: Market Characteristics
Exhibits12: Offerings of vendors included in the market definition
Exhibits13: Market segments
Exhibits14: Chart on Global – Market size and forecast 2023-2028 ($ million)
Exhibits15: Data Table on Global – Market size and forecast 2023-2028 ($ million)
Exhibits16: Chart on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits17: Data Table on Global Market: Year-over-year growth 2023-2028 (%)
Exhibits18: Historic Market Size – Data Table on global rheumatoid arthritis drugs market 2018 – 2022 ($ million)
Exhibits19: Historic Market Size – Drug Class Segment 2018 – 2022 ($ million)
Exhibits20: Historic Market Size – Type Segment 2018 – 2022 ($ million)
Exhibits21: Historic Market Size – Geography Segment 2018 – 2022 ($ million)
Exhibits22: Historic Market Size – Country Segment 2018 – 2022 ($ million)
Exhibits23: Five forces analysis – Comparison between 2023 and 2028
Exhibits24: Chart on Bargaining power of buyers – Impact of key factors 2023 and 2028
Exhibits25: Bargaining power of suppliers – Impact of key factors in 2023 and 2028
Exhibits26: Threat of new entrants – Impact of key factors in 2023 and 2028
Exhibits27: Threat of substitutes – Impact of key factors in 2023 and 2028
Exhibits28: Threat of rivalry – Impact of key factors in 2023 and 2028
Exhibits29: Chart on Market condition – Five forces 2023 and 2028
Exhibits30: Chart on Drug Class – Market share 2023-2028 (%)
Exhibits31: Data Table on Drug Class – Market share 2023-2028 (%)
Exhibits32: Chart on Comparison by Drug Class
Exhibits33: Data Table on Comparison by Drug Class
Exhibits34: Chart on Disease-modifying anti-rheumatic drugs – Market size and forecast 2023-2028 ($ million)
Exhibits35: Data Table on Disease-modifying anti-rheumatic drugs – Market size and forecast 2023-2028 ($ million)
Exhibits36: Chart on Disease-modifying anti-rheumatic drugs – Year-over-year growth 2023-2028 (%)
Exhibits37: Data Table on Disease-modifying anti-rheumatic drugs – Year-over-year growth 2023-2028 (%)
Exhibits38: Chart on Nonsteroidal anti-inflammatory drugs – Market size and forecast 2023-2028 ($ million)
Exhibits39: Data Table on Nonsteroidal anti-inflammatory drugs – Market size and forecast 2023-2028 ($ million)
Exhibits40: Chart on Nonsteroidal anti-inflammatory drugs – Year-over-year growth 2023-2028 (%)
Exhibits41: Data Table on Nonsteroidal anti-inflammatory drugs – Year-over-year growth 2023-2028 (%)
Exhibits42: Chart on Corticosteroids – Market size and forecast 2023-2028 ($ million)
Exhibits43: Data Table on Corticosteroids – Market size and forecast 2023-2028 ($ million)
Exhibits44: Chart on Corticosteroids – Year-over-year growth 2023-2028 (%)
Exhibits45: Data Table on Corticosteroids – Year-over-year growth 2023-2028 (%)
Exhibits46: Market opportunity by Drug Class ($ million)
Exhibits47: Data Table on Market opportunity by Drug Class ($ million)
Exhibits48: Chart on Type – Market share 2023-2028 (%)
Exhibits49: Data Table on Type – Market share 2023-2028 (%)
Exhibits50: Chart on Comparison by Type
Exhibits51: Data Table on Comparison by Type
Exhibits52: Chart on Biologics – Market size and forecast 2023-2028 ($ million)
Exhibits53: Data Table on Biologics – Market size and forecast 2023-2028 ($ million)
Exhibits54: Chart on Biologics – Year-over-year growth 2023-2028 (%)
Exhibits55: Data Table on Biologics – Year-over-year growth 2023-2028 (%)
Exhibits56: Chart on Small Molecules – Market size and forecast 2023-2028 ($ million)
Exhibits57: Data Table on Small Molecules – Market size and forecast 2023-2028 ($ million)
Exhibits58: Chart on Small Molecules – Year-over-year growth 2023-2028 (%)
Exhibits59: Data Table on Small Molecules – Year-over-year growth 2023-2028 (%)
Exhibits60: Market opportunity by Type ($ million)
Exhibits61: Data Table on Market opportunity by Type ($ million)
Exhibits62: Analysis of price sensitivity, lifecycle, customer purchase basket, adoption rates, and purchase criteria
Exhibits63: Chart on Market share By Geographical Landscape 2023-2028 (%)
Exhibits64: Data Table on Market share By Geographical Landscape 2023-2028 (%)
Exhibits65: Chart on Geographic comparison
Exhibits66: Data Table on Geographic comparison
Exhibits67: Chart on North America – Market size and forecast 2023-2028 ($ million)
Exhibits68: Data Table on North America – Market size and forecast 2023-2028 ($ million)
Exhibits69: Chart on North America – Year-over-year growth 2023-2028 (%)
Exhibits70: Data Table on North America – Year-over-year growth 2023-2028 (%)
Exhibits71: Chart on Europe – Market size and forecast 2023-2028 ($ million)
Exhibits72: Data Table on Europe – Market size and forecast 2023-2028 ($ million)
Exhibits73: Chart on Europe – Year-over-year growth 2023-2028 (%)
Exhibits74: Data Table on Europe – Year-over-year growth 2023-2028 (%)
Exhibits75: Chart on Asia – Market size and forecast 2023-2028 ($ million)
Exhibits76: Data Table on Asia – Market size and forecast 2023-2028 ($ million)
Exhibits77: Chart on Asia – Year-over-year growth 2023-2028 (%)
Exhibits78: Data Table on Asia – Year-over-year growth 2023-2028 (%)
Exhibits79: Chart on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
Exhibits80: Data Table on Rest of World (ROW) – Market size and forecast 2023-2028 ($ million)
Exhibits81: Chart on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
Exhibits82: Data Table on Rest of World (ROW) – Year-over-year growth 2023-2028 (%)
Exhibits83: Chart on US – Market size and forecast 2023-2028 ($ million)
Exhibits84: Data Table on US – Market size and forecast 2023-2028 ($ million)
Exhibits85: Chart on US – Year-over-year growth 2023-2028 (%)
Exhibits86: Data Table on US – Year-over-year growth 2023-2028 (%)
Exhibits87: Chart on UK – Market size and forecast 2023-2028 ($ million)
Exhibits88: Data Table on UK – Market size and forecast 2023-2028 ($ million)
Exhibits89: Chart on UK – Year-over-year growth 2023-2028 (%)
Exhibits90: Data Table on UK – Year-over-year growth 2023-2028 (%)
Exhibits91: Chart on China – Market size and forecast 2023-2028 ($ million)
Exhibits92: Data Table on China – Market size and forecast 2023-2028 ($ million)
Exhibits93: Chart on China – Year-over-year growth 2023-2028 (%)
Exhibits94: Data Table on China – Year-over-year growth 2023-2028 (%)
Exhibits95: Chart on Germany – Market size and forecast 2023-2028 ($ million)
Exhibits96: Data Table on Germany – Market size and forecast 2023-2028 ($ million)
Exhibits97: Chart on Germany – Year-over-year growth 2023-2028 (%)
Exhibits98: Data Table on Germany – Year-over-year growth 2023-2028 (%)
Exhibits99: Chart on France – Market size and forecast 2023-2028 ($ million)
Exhibits100: Data Table on France – Market size and forecast 2023-2028 ($ million)
Exhibits101: Chart on France – Year-over-year growth 2023-2028 (%)
Exhibits102: Data Table on France – Year-over-year growth 2023-2028 (%)
Exhibits103: Market opportunity By Geographical Landscape ($ million)
Exhibits104: Data Tables on Market opportunity By Geographical Landscape ($ million)
Exhibits105: Impact of drivers and challenges in 2023 and 2028
Exhibits106: Overview on Criticality of inputs and Factors of differentiation
Exhibits107: Overview on factors of disruption
Exhibits108: Impact of key risks on business
Exhibits109: Vendors covered
Exhibits110: Matrix on vendor position and classification
Exhibits111: AbbVie Inc. – Overview
Exhibits112: AbbVie Inc. – Product / Service
Exhibits113: AbbVie Inc. – Key news
Exhibits114: AbbVie Inc. – Key offerings
Exhibits115: Amgen Inc. – Overview
Exhibits116: Amgen Inc. – Product / Service
Exhibits117: Amgen Inc. – Key offerings
Exhibits118: Bristol Myers Squibb Co. – Overview
Exhibits119: Bristol Myers Squibb Co. – Product / Service
Exhibits120: Bristol Myers Squibb Co. – Key news
Exhibits121: Bristol Myers Squibb Co. – Key offerings
Exhibits122: Eli Lilly and Co. – Overview
Exhibits123: Eli Lilly and Co. – Product / Service
Exhibits124: Eli Lilly and Co. – Key news
Exhibits125: Eli Lilly and Co. – Key offerings
Exhibits126: F. Hoffmann La Roche Ltd. – Overview
Exhibits127: F. Hoffmann La Roche Ltd. – Business segments
Exhibits128: F. Hoffmann La Roche Ltd. – Key news
Exhibits129: F. Hoffmann La Roche Ltd. – Key offerings
Exhibits130: F. Hoffmann La Roche Ltd. – Segment focus
Exhibits131: Genor Biopharma Holdings Ltd. – Overview
Exhibits132: Genor Biopharma Holdings Ltd. – Product / Service
Exhibits133: Genor Biopharma Holdings Ltd. – Key offerings
Exhibits134: Gilead Sciences Inc. – Overview
Exhibits135: Gilead Sciences Inc. – Product / Service
Exhibits136: Gilead Sciences Inc. – Key news
Exhibits137: Gilead Sciences Inc. – Key offerings
Exhibits138: Johnson and Johnson – Overview
Exhibits139: Johnson and Johnson – Business segments
Exhibits140: Johnson and Johnson – Key news
Exhibits141: Johnson and Johnson – Key offerings
Exhibits142: Johnson and Johnson – Segment focus
Exhibits143: Kangstem Biotech Co. Ltd. – Overview
Exhibits144: Kangstem Biotech Co. Ltd. – Product / Service
Exhibits145: Kangstem Biotech Co. Ltd. – Key offerings
Exhibits146: Novartis AG – Overview
Exhibits147: Novartis AG – Business segments
Exhibits148: Novartis AG – Key offerings
Exhibits149: Novartis AG – Segment focus
Exhibits150: Oryn Therapeutics – Overview
Exhibits151: Oryn Therapeutics – Product / Service
Exhibits152: Oryn Therapeutics – Key offerings
Exhibits153: Pfizer Inc. – Overview
Exhibits154: Pfizer Inc. – Product / Service
Exhibits155: Pfizer Inc. – Key news
Exhibits156: Pfizer Inc. – Key offerings
Exhibits157: Sanofi – Overview
Exhibits158: Sanofi – Business segments
Exhibits159: Sanofi – Key news
Exhibits160: Sanofi – Key offerings
Exhibits161: Sanofi – Segment focus
Exhibits162: Sorrento Therapeutics Inc. – Overview
Exhibits163: Sorrento Therapeutics Inc. – Business segments
Exhibits164: Sorrento Therapeutics Inc. – Key offerings
Exhibits165: Sorrento Therapeutics Inc. – Segment focus
Exhibits166: UCB SA – Overview
Exhibits167: UCB SA – Product / Service
Exhibits168: UCB SA – Key offerings
Exhibits169: Inclusions checklist
Exhibits170: Exclusions checklist
Exhibits171: Currency conversion rates for US$
Exhibits172: Research methodology
Exhibits173: Validation techniques employed for market sizing
Exhibits174: Information sources
Exhibits175: List of abbreviations



❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ 世界の関節リウマチ治療薬市場2024-2028(Global Rheumatoid Arthritis Drugs Market 2024-2028)]についてメールでお問い合わせはこちらでお願いします。


◆H&Iグローバルリサーチのお客様(例)◆